BridgeMD
New treatment option for Chronic Lymphocytic Leukemia
Official title A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov ID: NCT06428019
What this study is testing
What is Venetoclax?
Venetoclax is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for chronic lymphocytic leukemia.
Also referred to as ABT-199.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of documented, previously untreated, chronic lymphocytic leukemia (CLL) requiring treatment according to the 2018 international workshop on...
- Previously untreated small lymphocytic lymphoma (SLL) meeting the 2018 iwCLL criteria for treatment will also be equally considered as CLL for...
- Eastern Cooperative Oncology Group (ECOG) performance status \<= 2.
- Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening, unless cytopenia is due to marrow...
- Creatinine clearance (CrCl) \>= 30 mL/min using the Cockcroft-Gault formula are eligible for inclusion.
You likely can't join if
- \- Active/uncontrolled infection, no Richter's transformation, no active immune thrombocytopenia.
The study team makes the final eligibility decision.
Where it's taking place
- Tucson, Arizona, United States
- Clovis, California, United States
- Los Angeles, California, United States
- Aurora, Colorado, United States
- New Haven, Connecticut, United States
- Gainesville, Florida, United States
- Jacksonville, Florida, United States
- Orange City, Florida, United States
- St. Petersburg, Florida, United States
- Springfield, Illinois, United States
- Dyer, Indiana, United States
- Des Moines, Iowa, United States
- Shreveport, Louisiana, United States
- Bethesda, Maryland, United States
- Silver Spring, Maryland, United States
- Worcester, Massachusetts, United States
- Detroit, Michigan, United States
- Kansas City, Missouri, United States
- New York, New York, United States
- Charlotte, North Carolina, United States
+ 44 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tucson, Arizona, United States; Clovis, California, United States; Los Angeles, California, United States; Aurora, Colorado, United States; New Haven, Connecticut, United States; Gainesville, Florida, United States and 58 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.